Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이향운 | * |
dc.date.accessioned | 2017-04-25T01:04:23Z | - |
dc.date.available | 2017-04-25T01:04:23Z | - |
dc.date.issued | 2017 | * |
dc.identifier.issn | 0013-9580 | * |
dc.identifier.issn | 1528-1167 | * |
dc.identifier.other | OAK-20446 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/234995 | - |
dc.description.abstract | This open-label, multicenter, randomized phase IV trial (NCT01498822) of noninferiority design compared the long-term effectiveness, safety, and tolerability of levetiracetam (LEV) monotherapy with those of oxcarbazepine (OXC) monotherapy in adults with newly diagnosed focal epilepsy. Korean patients (16-80years), with 2 unprovoked focal seizures in the year preceding the trial, who had not taken any antiepileptic drugs (AEDs) in the last 6months, were randomized to receive LEV or OXC (1:1). Effectiveness, safety, and tolerability were assessed over a 50-week period. Treatment failure rates (per protocol set) were 15/118 (12.7%) in the LEV-treated group and 30/128 (23.4%) in the OXC-treated group, an absolute difference of -10.7% (95% confidence interval [CI] -20.2, -1.2). Because the upper 95% CI limit was less than the pre-specified noninferiority margin of 15%, LEV was considered noninferior to OXC. Twenty-four-week and 48-week seizure freedom rates were 53.8% and 34.7% for LEV vs. 58.5% and 40.9% for OXC. Both LEV and OXC were well tolerated, with 8.7% and 8.6% of patients reporting serious treatment-emergent adverse events, respectively. By comparing LEV with OXC, another newer AED, LEV can be considered a useful option as initial monotherapy for patients with newly diagnosed focal epilepsy. | * |
dc.language | English | * |
dc.publisher | WILEY | * |
dc.subject | Seizures | * |
dc.subject | Antiepileptic drugs | * |
dc.subject | Effectiveness | * |
dc.subject | Safety | * |
dc.subject | Tolerability | * |
dc.title | Comparison of levetiracetam and oxcarbazepine monotherapy among Korean patients with newly diagnosed focal epilepsy: A long-term, randomized, open-label trial | * |
dc.type | Article | * |
dc.relation.issue | 4 | * |
dc.relation.volume | 58 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | E70 | * |
dc.relation.lastpage | E74 | * |
dc.relation.journaltitle | EPILEPSIA | * |
dc.identifier.doi | 10.1111/epi.13707 | * |
dc.identifier.wosid | WOS:000398861000005 | * |
dc.identifier.scopusid | 2-s2.0-85017294964 | * |
dc.author.google | Kim, Ji Hyun | * |
dc.author.google | Lee, Sang Kun | * |
dc.author.google | Loesch, Christian | * |
dc.author.google | Namgoong, Kyungsun | * |
dc.author.google | Lee, Hyang Woon | * |
dc.author.google | Hong, Seung Bong|Korean N01367 Study Grp | * |
dc.contributor.scopusid | 이향운(34667959700) | * |
dc.date.modifydate | 20240123091326 | * |